CytoMed Therapeutics Announces Novel First-In-Human Clinical Trial Collaborations with Renowned and Prestigious Hospital Partner to Advance Its Off-The-Shelf Donor-Derived Gamma Delta T Ce...
CytoMed Therapeutics Limited - Ordinary Shares (GDTC)
Company Research
Source: GlobeNewswire
SINGAPORE, Dec. 08, 2025 (GLOBE NEWSWIRE) -- CytoMed Therapeutics Limited (NASDAQ: GDTC) (“CytoMed” or the “Company”), a Singapore-based clinical stage biopharmaceutical company focused on harnessing its proprietary technologies to develop novel affordable donor-derived cell-based immunotherapies for the treatment of a broad range of cancers, including both blood and solid tumors, today announced that it has entered into a Memorandum of Understanding with Universiti Malaya Medical Centre (“UMMC”) a teaching hospital under Universiti Malaya to establish a multi-site, first-in-human Phase I clinical trial to investigate the safety and efficacy of CytoMed’s patented allogeneic unmodified Gamma Delta (?d) T cells (“CTM-GDT”) (without genetically modifying the cells to express any receptor) for no-option cancer patients in Malaysia. This initiative complements CytoMed’s ongoing first-in-human Phase I chimeric antigen receptor (“CAR”) T clinical trial at National University Hospital Sing
Show less
Read more
Impact Snapshot
Event Time:
GDTC
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
GDTC alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
GDTC alerts
High impacting CytoMed Therapeutics Limited - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
GDTC
News
- CytoMed Therapeutics Completes Acquisition of T Cell Technology from UK to Treat Cancers in China and IndiaGlobeNewswire
- CytoMed Therapeutics Secures Non-Dilutive Investment for Subsidiary LongevityBank from ICH Capital and Updates on New China StrategyGlobeNewswire
- CytoMed Therapeutics’ Chairman Increases Effective Holdings to 21.95%GlobeNewswire
- Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market SurgePR Newswire
- Cellular Immunotherapy Breakthroughs Fuel $370 Billion Market SurgePR Newswire
GDTC
Sec Filings
- 12/8/25 - Form 6-K
- 11/18/25 - Form 6-K
- 11/6/25 - Form 6-K
- GDTC's page on the SEC website